Skip to content
AnalystLens

Halozyme Therapeutics 8-K Report, Financial Results (Aug 6, 2026)

Reports
Earnings & Results·Exhibits & Filings
Filing Date
Filed August 6, 2026
Period End
August 6, 2026
Security
HALO
In the record · 2016–202610-K1110-Q338-K141

HALO filed 11 annual reports (10-K), 33 quarterly reports (10-Q) and 141 current reports (8-K) between 2016 and 2026.

  1. Material agreement8-K · Jul ’17Jul ’17
  2. Leadership change8-K · Feb ’20Feb ’20
  3. Deal closed8-K · May ’22May ’22
  4. Leadership change8-K · Oct ’25Oct ’25

Summary

Summary of the 8-K filed August 6, 2026. Cited figures are marked; the original filing is the authoritative source.

Halozyme Therapeutics, Inc. reported record second-quarter 2026 results in a press release furnished as Exhibit 99.1 to this Form 8-K.

Total revenue was $481.0 milliona, up from $325.7 million in the second quarter of 2025, driven by royalty revenue of $307.7 million (compared with $205.6 million) and higher product sales. Net income was $229.9 million, or $1.90 per diluted share (GAAP), compared with $165.2 million, or $1.33, a year earlier. Non-GAAP diluted EPS was $2.28, compared with $1.54, and adjusted EBITDA was $328.8 million, compared with $225.5 million.

The company raised its full-year 2026 guidance. Total revenue is now expected at $1.835 billion to $1.910 billionb (previously $1.710 billion to $1.810 billion), royalty revenue at $1.220 billion to $1.245 billion, adjusted EBITDA at $1.225 billion to $1.280 billion, and non-GAAP diluted EPS at $8.65 to $9.00. The guidance includes approximately $60 million of new Hypercon and Surf Bio investments.

Management stated that the company has signed five new ENHANZE and Hypercon collaborations year to date, exceeding its goal of three for the full year. On capital allocation, Halozyme repurchased $333 millionc of shares in the second quarter at an average price of $69.30 under its May 2026 and February 2024 programs.

The May 2026 program authorizes up to $1.0 billiond of repurchases through December 31, 2028, with an expectation of at least $400 million of buybacks in 2026. Cash, cash equivalents, restricted cash and marketable securities totaled $231.9 million at June 30, 2026, and total debt-related balances on the balance sheet include $209.0 million current and $1.94 billion long-term.

Key Highlights

  1. Q2 2026 total revenue of $481.0 million, up from $325.7 million in Q2 2025; royalty revenue of $307.7 million, up from $205.6 million.
  2. Q2 2026 net income of $229.9 million (GAAP diluted EPS $1.90) versus $165.2 million (GAAP diluted EPS $1.33) a year earlier.
  3. Adjusted EBITDA of $328.8 million for Q2 2026, compared with $225.5 million in Q2 2025; non-GAAP diluted EPS of $2.28 versus $1.54.
  4. 2026 guidance raised: total revenue of $1.835–$1.910 billion, royalty revenue of $1.220–$1.245 billion, adjusted EBITDA of $1.225–$1.280 billion, and non-GAAP diluted EPS of $8.65–$9.00.
  5. Five new ENHANZE and Hypercon collaborations signed year to date through July 2026, including agreements with Vertex, Oruka, GSK, Incyte and an undisclosed partner.
  6. Repurchased $333 million of shares in Q2 2026 at an average price of $69.30; new program authorizes up to $1.0 billion through December 31, 2028, with at least $400 million expected in 2026.
  7. Cash, cash equivalents, restricted cash and marketable securities of $231.9 million at June 30, 2026, versus $145.4 million at December 31, 2025, primarily from operating cash generation.

Frequently Asked Questions

  1. What drove the increase in second-quarter 2026 revenue?

    The filing attributes the 48% year-over-year increase in total revenue to royalty revenue growth and higher product sales. Royalty revenue rose to $307.7 million from $205.6 million, primarily from uptake of ENHANZE partner products launched since 2020, predominantly VYVGART Hytrulo by argenx and DARZALEX SC by Janssen, plus other recently launched products.

  2. How much did Halozyme raise its 2026 guidance?

    Total revenue guidance increased to $1.835–$1.910 billion from $1.710–$1.810 billion, and royalty revenue guidance increased to $1.220–$1.245 billion from $1.130–$1.170 billion. Adjusted EBITDA guidance rose to $1.225–$1.280 billion from $1.125–$1.205 billion, and non-GAAP diluted EPS guidance rose to $8.65–$9.00 from $7.75–$8.25.

  3. What is the status of the share repurchase program?

    In May 2026 the company announced a program to repurchase up to $1.0 billion of common stock by December 31, 2028, with an expectation of buying back at least $400 million in 2026. In Q2 2026 it repurchased 4.8 million shares for $332.8 million at an average price of $69.30 under the May 2026 and February 2024 programs; the February 2024 program was completed in June 2026. The guidance does not consider the impact of potential future repurchases.

  4. What new collaborations did Halozyme announce?

    The filing describes an April 2026 agreement with Vertex for Hypercon technology (with a $15 million upfront payment), a May 2026 agreement with GSK for ENHANZE across multiple oncology targets, a May 2026 agreement with Oruka for Hypercon use with ORKA-001, a May 2026 agreement with an undisclosed company for a nucleic acid therapeutic, and a July 2026 agreement with Incyte to evaluate subcutaneous formulations of INCA033989.

  5. Is the earnings press release considered filed with the SEC?

    The press release dated August 6, 2026, is attached as Exhibit 99.1 and is furnished under Item 2.02. The filing states that it shall not be deemed filed for purposes of Section 18 of the Exchange Act and is not incorporated by reference into other filings unless specifically stated.